SCHEMBL626870

SCHEMBL626870

OBOc1ccc(Cl)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.42
CYP2A6 P11509 1/20 0.42
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
HPGD P15428 2/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
CYP1A2 P05177 2/20 0.38
CYP2D6 P10635 2/20 0.38
MAPT P10636 2/20 0.38
CYP2C19 P33261 2/20 0.38
CYP3A4 P08684 1/20 0.38
PPARA Q07869 1/20 0.38
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
CES2 O00748 1/20 0.35
CES1 P23141 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15181513 0.93 MAOA (0.52) LMNAMAOAMAOBHPGDMEN1
SCHEMBL15850877 0.93 CYP1A2 (0.42) LMNACYP2A6MAOAMAOBHPGD
SCHEMBL14477632 0.86 MEN1 (0.33) MEN1KMT2ACA1CA2CA9
SCHEMBL98774 0.78 LMNA (0.47) LMNACYP2A6MAOAMAOBHPGD
SCHEMBL79980 0.76 ESR2 (0.52) LMNAHPGDMEN1KMT2ACA1
SCHEMBL2602434 0.74 ACHE (0.48) LMNAMEN1KMT2ACA1CA2
SCHEMBL819491 0.74 CYP2A6 (0.42) LMNACYP2A6MAOAMAOBMEN1
SCHEMBL819814 0.74 CA1 (0.58) CA1CA2CA9MAPTCYP3A4
SCHEMBL5148477 0.74 ALDH1A1 (0.50) MAOAMAOBHPGDMEN1KMT2A
SCHEMBL121643 0.74 NFE2L2 (0.37) LMNAMAOAMAOBCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101333226-A Chiral dual ring [4.4.0] diborate and method for preparing same UNIV WUHAN (CN) 2008-12-31 CN claimed
US-20240228470-A1 Organic Compound And Organic Light Emitting Device Including Same P&H TECH CO., LTD (KR) 2024-07-11 US disclosed
US-12029112-B2 Composition for optoelectronic device and organic optoelectronic device and display device SAMSUNG SDI CO., LTD. (KR) 2024-07-02 US disclosed
US-20240023432-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER LT MATERIALS CO., LTD. (KR) 2024-01-18 US disclosed
US-20240018103-A1 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST RAQUALIA PHARMA INC. (JP) 2024-01-18 US disclosed
US-11840513-B2 Substituted nicotinimide inhibitors of BTK for treating cancer Guangzhou Innocare Pharma Tech Co., Ltd (CN) 2023-12-12 US disclosed
US-20230389347-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO.,LTD. (JP) 2023-11-30 US disclosed
US-11832512-B2 Organic electroluminescence device and monoamine compound for organic electroluminescence device SAMSUNG DISPLAY CO., LTD. (KR) 2023-11-28 US disclosed
US-20230371368-A1 LIGHT EMITTING ELEMENT AND AMINE COMPOUND FOR THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2023-11-16 US disclosed
US-11805697-B2 Organic electroluminescence device and monoamine compound for organic electroluminescence device SAMSUNG DISPLAY CO., LTD. (KR) 2023-10-31 US disclosed
US-20120112174-A1 COMPOUND FOR ORGANIC OPTOELECTRONIC DEVICE, ORGANIC LIGHT EMITTING DIODE INCLUDING THE SAME AND DISPLAY DEVICE INCLUDING THE ORGANIC LIGHT EMITTING DIODE CHEIL INDUSTRIES, INC. (KR) 2012-05-10 US disclosed
US-20120095017-A1 PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-04-19 US disclosed
US-20120043531-A1 COMPOUND FOR ORGANIC OPTOELECTRONIC DEVICE, ORGANIC LIGHT EMITTING DIODE INCLUDING THE SAME, AND DISPLAY DEVICE INCLUDING THE LIGHT EMITTING DIODE CHEIL INDUSTRIES, INC. (KR) 2012-02-23 US disclosed
WO-2012020848-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-16 WO disclosed
US-20110245268-A1 PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2011-10-06 US disclosed
US-20110118279-A1 PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2011-05-19 US disclosed
US-20110009415-A1 Thienopyridazine Compounds, Their Preparations, Pharmaceutical Compositions And Uses WU, ZHANGGUI (CN) 2011-01-13 US disclosed
US-20100256365-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. 2010-10-07 US disclosed
CN-101333226-A Chiral dual ring [4.4.0] diborate and method for preparing same UNIV WUHAN (CN) 2008-12-31 CN disclosed
CN-1282326-A Anilide derivative, process for producing the same, and use thereof TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2001-01-31 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120112174-A1 COMPOUND FOR ORGANIC OPTOELECTRONIC DEVICE, ORGANIC LIGHT EMITTING DIODE INCLUDING THE SAME AND DISPLAY DEVICE INCLUDING THE ORGANIC LIGHT EMITTING DIODE AOX1, OCIAD1, OCIAD2 LMNA 4819/4885CYP2A6 411/4885MAOA 147/4885
US-20240018103-A1 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST CRHR2, CRHR1, CRH LMNA 3693/4885CYP2A6 1081/4885MAOA 642/4885
US-20110009415-A1 Thienopyridazine Compounds, Their Preparations, Pharmaceutical Compositions And Uses CYP3A5, ABCC5, DPYD LMNA 4144/4885CYP2A6 66/4885MAOA 2049/4885
US-20110245268-A1 PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS PREP, PEPD, DNPEP LMNA 4581/4885CYP2A6 575/4885MAOA 316/4885
US-20240023432-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER CYP1B1, NOTUM, CYP4F11 LMNA 1971/4885CYP2A6 241/4885MAOA 581/4885
US-11805697-B2 Organic electroluminescence device and monoamine compound for organic electroluminescence device SLC18A2, SLC18A1, MAOA LMNA 3034/4885CYP2A6 758/4885MAOA 3/4885
US-20230371368-A1 LIGHT EMITTING ELEMENT AND AMINE COMPOUND FOR THE SAME SLC1A2, SLC18A1, SLC18A2 LMNA 1964/4885CYP2A6 2090/4885MAOA 10/4885
US-20240228470-A1 Organic Compound And Organic Light Emitting Device Including Same OR10J3, ORMDL3, OR51E2 LMNA 3738/4885CYP2A6 1839/4885MAOA 635/4885
US-20230389347-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE LEF1, L1CAM, RER1 LMNA 847/4885CYP2A6 2780/4885MAOA 1303/4885
US-20120095017-A1 PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS PREP, PEPD, DNPEP LMNA 4581/4885CYP2A6 575/4885MAOA 316/4885
US-11832512-B2 Organic electroluminescence device and monoamine compound for organic electroluminescence device MAOA, MAOB, AOC2 LMNA 4156/4885CYP2A6 597/4885MAOA 1/4885
US-20100256365-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, MAP3K13, MAP3K8 LMNA 2202/4885CYP2A6 4605/4885MAOA 4445/4885
US-20120043531-A1 COMPOUND FOR ORGANIC OPTOELECTRONIC DEVICE, ORGANIC LIGHT EMITTING DIODE INCLUDING THE SAME, AND DISPLAY DEVICE INCLUDING THE LIGHT EMITTING DIODE AOX1, OR10J3, OCIAD1 LMNA 4792/4885CYP2A6 634/4885MAOA 252/4885
US-12029112-B2 Composition for optoelectronic device and organic optoelectronic device and display device OR10J3, OCIAD2, OCIAD1 LMNA 4756/4885CYP2A6 2129/4885MAOA 400/4885
US-20110118279-A1 PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS PREP, PEPD, DNPEP LMNA 4581/4885CYP2A6 575/4885MAOA 316/4885
US-11840513-B2 Substituted nicotinimide inhibitors of BTK for treating cancer BTK, SYK, LYN LMNA 3824/4885CYP2A6 2807/4885MAOA 1681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.